Facebook
Twitter
LinkedIn
ForwardNCCN 2023 Congress: Biomarkers in Solid Tumors
This program includes educational sessions and clinical scenarios focused on the rapidly evolving area of biomarker testing in oncology.
Target Audience
This educational program is designed to meet the educational needs of physicians, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with solid tumors.
Learning Objectives
The goal of this congress is to ensure that members of the interprofessional oncology care team, including physicians, nurse practitioners, nurses, physician assistants, pharmacists, and other relevant healthcare professionals, have the knowledge and skills necessary to:
- Apply the current standards of oncology care and the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) to appropriately integrate biomarker testing to optimize the care of patients with solid tumors.
- Select the appropriate biomarker tests to evaluate and optimally manage patients with solid tumors.
- Analyze and interpret the results of biomarker tests to select appropriate treatments for patients.
- Communicate the results of biomarker tests with patients to inform their care.
- Communicate with members of the interprofessional oncology care team about the use of biomarker testing in the management of patients with solid tumors.
Click here to view the learning objectives for each individual session.
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Faculty Disclosures
Congress Co-Moderators
The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Anthony J. Olszanski, MD, RPh
Bristol-Myers Squibb Company: Scientific Advisor
Eisai Inc.: Scientific Advisor
InstilBio: Scientific Advisor
Merck & Co., Inc.: Scientific Advisor
Nektar Therapeutics: Scientific Advisor
Novartis Pharmaceuticals Corporation: Scientific Advisor
Oncosec Immunotherapies: Scientific Advisor
Pfizer Inc.: Honoraria
Takeda Pharmaceuticals North America, Inc.: Scientific Advisor
Tuya Pal, MD
Natera, Inc.: Scientific Advisor
Presenting Faculty
The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.
Harold J. Burstein, MD, PhD
Craig M. Horbinski, MD, PhD
Lawrence J. Jennings, MD, PhD
Grace Y. Lin, MD, PhD
Daniel J. McGrail, PhD
Lisa Schlager
Randy Vince Jr., MD, MS
The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Devon Adams, RN, MPH
Amgen Inc.: Grant/Research Support
Bayer HealthCare: Grant/Research Support
Blueprint Medicines: Grant/Research Support
Bristol-Myers Squibb Company: Grant/Research Support
EMD Serono: Grant/Research Support
Foundation Medicine, Inc.: Grant/Research Support
Genentech, Inc.: Grant/Research Support
Janssen Pharmaceutica Products, LP: Grant/Research Support
Merck & Co., Inc.: Grant/Research Support
NeoGenomics Laboratories, Inc.: Grant/Research Support
Pfizer Inc.: Grant/Research Support
sanofi-aventis U.S.: Grant/Research Support
Gabriel A. Bien-Willner, MD, PhD
Guardant Health: Equity Interest/Stock Options
Illumina, Inc.: Scientific Advisor
Merck & Co., Inc.: Scientific Advisor
Aparna Kalyan, MD
AstraZeneca Pharmaceuticals LP: Consulting Fee; Scientific Advisor
Boston Scientific Corporation: Consulting Fee; Honoraria; Scientific Advisor
Exelixis Inc.: Consulting Fee; Honoraria; Scientific Advisor
Genentech, Inc.: Consulting Fee; Honoraria; Scientific Advisor
QED Therapeutics, Inc.: Consulting Fee; Scientific Advisor
Rimas V. Lukas, MD
Bristol-Myers Squibb Company: Grant/Research Support
Merck & Co., Inc.: Product/Speakers Bureau; Scientific Advisor
Novocure: Product/Speakers Bureau
Jennifer Morrissette, PhD
AbbVie, Inc.: Consulting Fee
Illumina, Inc.: Consulting Fee
Thermo Fisher Scientific, Inc.: Equity Interest/Stock Options
Sandip P. Patel, MD
Amgen Inc.: Grant/Research Support; Scientific Advisor
AstraZeneca Pharmaceuticals LP: Grant/Research Support; Scientific Advisor
Bristol-Myers Squibb Company: Grant/Research Support; Scientific Advisor
Eli Lilly and Company: Scientific Advisor
Fate Therapeutics: Grant/Research Support
Genentech, Inc.: Grant/Research Support; Scientific Advisor
Iovance pharmaceuticals: Grant/Research Support; Scientific Advisor
Merck & Co., Inc.: Grant/Research Support; Scientific Advisor
Novartis Pharmaceuticals Corporation: Grant/Research Support; Scientific Advisor
Pfizer Inc.: Grant/Research Support; Scientific Advisor
SQZ Biotech, Inc.: Grant/Research Support
Daniel E. Spratt, MD
Bayer HealthCare: Consulting Fee
Blue Earth Diagnostics: Honoraria
Novartis Pharmaceuticals Corporation: Honoraria
Pfizer Inc.: Honoraria
Varian Medical Systems, Inc.: Honoraria
Howard (Jack) West, MD
Amgen Inc.: Consulting Fee
AstraZeneca Pharmaceuticals LP: Consulting Fee; Product/Speakers Bureau
Boehringer Ingelheim GmbH: Consulting Fee
Daiichi-Sankyo Co.: Consulting Fee
Genentech/Roche: Consulting Fee
Merck & Co., Inc.: Consulting Fee; Product/Speakers Bureau
Mirati Therapeutics, Inc.: Consulting Fee
Regeneron Pharmaceuticals, Inc.: Consulting Fee
Summit Therapeutics Inc.: Consulting Fee
Takeda Pharmaceuticals North America, Inc.: Consulting Fee
Moderator/Planner Disclosures
The moderator/planner listed below has the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for this individual have been mitigated.
Crystal S. Denlinger, MD
Agios, Inc.: Grant/Research Support
Amgen Inc.: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Grant/Research Support
BeiGene: Scientific Advisor; Grant/Research Support
Bristol-Myers Squibb Company: Scientific Advisor; Grant/Research Support
Eli Lilly and Company: Grant/Research Support
Exelixis Inc.: Grant/Research Support
Genmab: Grant/Research Support
MacroGenics: Grant/Research Support
MedImmune Inc: Grant/Research Support
Merck & Co., Inc.: Scientific Advisor
sanofi-aventis U.S.: Grant/Research Support
Taiho Pharmaceutials Co., Ltd.: Scientific Advisor
Zymeworks: Scientific Advisor; Grant/Research Support
NCCN Staff Disclosures
None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
NCCN designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
NCCN designates this educational activity for a maximum of 6.75 contact hours.
Pharmacists
NCCN designates this knowledge-based continuing education activity for 6.75 contact hours (0.675 CEUs) of continuing education credit. UAN: JA4008196-0000-23-019-L01-P
PAs
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 6.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
American Board of Internal Medicine Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Aggregated participant data will be shared with the commercial supporters of this activity.
American Board of Pathology Continuing Certification (CC)
This activity has been registered to offer credit in the American Board of Pathology’s (ABPath) Continuing Certification program. Participants may earn up to 6.75 Lifelong Learning (Part II) credits.
Aggregated participant data will be shared with the commercial supporters of this activity.
American Board of Medical Specialties (MOC)
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory, the NCCN 2023 Congress: Biomarkers in Solid Tumors has met the requirements as a MOC Part II CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:
ABMS MOC Part II CME Activity
Medical Genetics and Genomics
Preventive Medicine
Psychiatry and Neurology
Radiology
Urology
Available Credit
- 6.75 AAPA Category 1 CME credit
- 6.75 AMA PRA Category 1 Credit™
- 6.75 ANCC contact hours
- 6.75 Participation
Price
Please log in with the email address you used for event registration.
Click the Take Course button to start the credit claiming process and/or view recorded presentations.
CE/MOC credit should be claimed for the congress as a whole, not session by session. You may claim credit for the congress only one time. When calculating your total credits, you should take into account all of the sessions you viewed either live or via recording.
Pharmacists: you must complete all requirements for credit by June 26, 2023.
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing